Indication

STELARA SQ® is indicated to treat:

  • Crohn’s Disease
  • Plaque Psoriasis
  • Psoriatic Arthritis

Drug Summary

STELARA, Ustekinumab, is an immunosuppressive drug that reduces inflammation in the body due to various automimmune diseases.For patient’s with Crohn’s disease, administration of STELARA is a regimen 1 intravenous infusion therapy followed by a maintenance dose of subcutaneous injections every 8 weeks. Patients with Plaque Psoriasis and Psoriatic Arthritis, STELARA is administred subcutaneously at week 1 and then week 4, followed by every 12 weeks regimen.

 

More Information

For more information, click here to visit the manufacturer’s website: https://www.stelarainfo.com/

Ready to Start with Specialty Infusion?

It’s easy to transition your treatment to Specialty Infusion. Here’s how it works:

Ask your doctor to send a prescription, clinical notes, demographics and your insurance card.

One of our Care Coordinators will contact you to confirm receipt of your referral and provide guidance on the next steps.

Your Care Coordinator will contact your insurance company to conduct an investigation of benefits and initiate authorization to ensure coverage of your treatment.

Our team works diligently to expedite the authorization process. Once approval is obtained, your Care Coordinator will contact you to schedule an appointment.